Last reviewed · How we verify
NCT06671457
Model-Driven Individualized Transcranial Direct Current Stimulation for the Treatment of Insomnia Disorders
NA trial testing Active transcranial direct current stimulation in Insomnia in 40 participants. Currently enrolling.
1 March 2026
Quick facts
| Lead sponsor | Zhen Wang |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 10 November 2024 |
| Primary completion | 1 March 2026 |
| Estimated completion | 1 April 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Active transcranial direct current stimulation
- Sham transcranial direct current stimulation
Conditions studied
- Insomnia — all drugs for Insomnia →
Sponsor
Zhen Wang — full company profile →
Who can join
Adults 18 to 65, any sex, with Insomnia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is designed to evaluate the efficacy and to explore the best individualized stimulus paradigm of transcranial Electrical Stimulation for insomnia patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Model-driven individualized transcranial direct current stimulation for the treatment of insomnia disorder: protocol for a randomized, sham-controlled, double-blind study.
Wang Y, Jia W, Zhang Z, Bai T, et al · · 2025 · PMID 41013363 · DOI 10.1186/s12888-025-07347-5
Verify or expand the search:
- PubMed search for NCT06671457
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Active transcranial direct current stimulation
Trials testing the same drug.
- NCT06834217 — Transcranial Direct Current Stimulation and Extinction in Obsessive Compulsive Disorder · NA · recruiting
- NCT06245070 — Speech and Voice Outcomes Following HD-tDCS Over the Left SMA · NA · not yet recruiting
- NCT06818240 — Transcranial Direct Current Stimulation Enhances Dual-task Performance in Stroke · NA · recruiting
- NCT04667221 — Cognitive Improvement Through tDCS for Patients With Multiple Sclerosis · NA · unknown
Other recruiting trials for Insomnia
Currently open trials in the same condition.
- NCT07384429 — Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease · Phase 4 · recruiting
- NCT07270406 — Healthy Behaviors for Insomnia Prevention in People With HIV and Ongoing Pain · NA · recruiting
- NCT07071324 — CF Wellness Program · NA · recruiting
- NCT07417813 — A Multicenter Observational Study of Lemborexant on Insomnia Patients With Psychiatric Disorders · recruiting
- NCT06348082 — Project Women's Insomnia Sleep Health Equity Study (WISHES) · NA · recruiting
Other Zhen Wang trials
Trials by the same sponsor.
- NCT06776354 — AI in Hypertension Treatment Education: Comparing GPT and Traditional Methods · NA · completed
- NCT06766383 — Simulated Patient and AI-based Roleplay for History-taking · NA · completed
- NCT06692114 — Efficacy and Influencing Factors of Deep Transcranial Magnetic Stimulation in the Treatment of OCD · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06671457 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhen Wang
- Last refreshed: 21 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06671457.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing